Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji)

Clinical Cancer Research

Volumn 3, Issue 1, 1997, Pages 71-79

  DeNardo, Gerald L ^a,d   Kukis, David L ^a   Shen, Sui ^a   Mausner, Leonard F ^b   Meares, Claude F ^c   Srivastava, Suresh C ^b   Miers, Laird A ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; COPPER 67; MONOCLONAL ANTIBODY LYM 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; COPPER 67 2IT BAT LYM 1; COPPER-67-2IT-BAT-LYM-1; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT; BURKITT LYMPHOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; RADIOMETRY; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BURKITT LYMPHOMA; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOCONJUGATES; MICE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; RADIOMETRY; RADIOPHARMACEUTICALS; WEIGHT LOSS;

EID: 0030608635     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. 131I] anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1994.
2. Lewis, J. P., DeNardo, G. L., and DeNardo, S. J. Radioimmuno- therapy of lymphoma: a UC Davis experience. Hybridoma, 14: 115- 120, 1995.
3. Armitage, J. O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med., 328: 1023-1030, 1993.
4. Press, O. W., Eary, J. P., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Blutchko, G. P., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeledantibody therapy of B-cell lymphoma with autologous bone marrow support. N. EngI. J. Med., 329: 1219-1224, 1994.
5. Bernstein, I. D., Eary, J. F., Badger, C. C., Press, O. W., Appelbaum, F. R., Martin, P. J., Krohn, K. A., Nelp, W. B., Porter, B., Fisher, D., Miller, R., Brown, S., Levy, R., and Thomas, E. D. High dose radiolabeled antibody therapy of lymphoma. Cancer Res., 50 (Suppl.); 1017s- 1021s, 1990.
6. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegal, J. A., Izon, D. O., Burger, K., Swayne, L. C., Belisle, E., Hansen, H. J., and Pinsky, C. M. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
7. Czuczman, M. S., Straus, D. J., Divgi, C. R., Graham, M., Garin- Chesa, P., Finn, R., Myers, J., Old, L. J., Larson, S. M., and Scheinberg, D. A. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 11: 2021-2029, 1993.
8. Kaminski, M. S., Fig, L. M., Zasadny, K. R., Koral, K. F., DelRosario, R. B., Francis, I. R., Hanson, C. A., Normolle, D. P., Mudgett, E., Liu, C. P., Moon, S., Scott, P., Miller, R. A., and Wahl, R. L. Imaging, dosimetry, and radioimmunotherapy with iodine 131- labeled anti-CD37 antibody in B-cell lymphoma. J. Clin. Oncol., 10: 1696-1711, 1992.
9. 131I-Lym-1. Cancer Res., 50 (Suppl.): 1014s-1016s, 1990.
10. Eary, J. F. Radioimmunotherapy of B-cell lymphoma. Ann. Oncol., 2 (Suppl. 2): 187-190, 1991.
11. Lim, S. H., and Marcus, R. E. Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas. Blood Rev., 6: 157-162, 1992.
12. Langmuir, V. Radioimmunotherapy: clinical results and dosimetric considerations. Nucl. Med. Biol., 19: 213-225, 1992.
13. Larson, S. M., Macapinlac, H. A., Scott, A. M., and Divgi, C. R. Recent achievements in the development of radiolabe led monoclonal antibodies for diagnosis, therapy, and biologic characterization of human tumors. Acta Oncol., 32: 709-715, 1993.
14. DeNardo, G. L., Mills, S. L., Kukis, D. L., Anderson, V., and DeNardo, S. J. Review of a four-year experience iodinating monoclonal antibodies with therapeutic amounts of I-131. Antib. Immunoconjug. Radiopharm., 8: 1-10, 1995.
15. Goldenberg, D. M. Radioimmunotherapy of cancer: arming the missiles. J. Nucl. Med., 33: 1110-1112, 1992.
16. Mausner, L. F., and Srivastava, S. C. Selection of radionuclides for radioimmunotherapy. Med. Phys., 20: 503-509, 1993.
17. Jungerman, J. A., Yu, K-H. P., and Zanelli, C. I. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. Int. J. Appl. Radiat. Isot., 35: 883-888, 1984.
18. Goldenberg, D. M. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J. Clin., 44: 43-64, 1994.
19. Yorke, E. D., Beaumier, P. L., Wessels, B. W., Fritzberg, A. R., and Morgan, C. A., Jr. Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Nucl. Med. Biol., 18: 827-835, 1991.
20. Sharkey, R. M., Motta-Hennessy, C., Pawlyk, D., Siegal, J. A., and Goldenberg, D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonie tumor xenografts. Cancer Res., 50: 2330-2336, 1990.
21. Khaw, B. A., Cooney, J., Edgington, T., and Strauss, H. W. Differences in experimental tumor localization of dual-labeled monoclonal antibody. J. Nucl. Med., 27: 1293-1299, 1986.
22. DeNardo, G. L., DeNardo, S. J., Miyao, N. P., Mills, S. J., Peng, J-S., O'Grady, L. F., Epstein, A. L., and Young, W. C. Non-dehalogenation mechanisms for excretion of radioiodine after administration of labeled antibodies. Int. J. Biol. Markers, 3: 1-9, 1988.
23. Mattes, M. J., Griffiths, G. L., Diril, H., Goldenberg, D. M., Ong, G. L., and Shin, L. B. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer (Phila.), 73 (Suppl.): 787-793, 1994.
24. DeNardo, G. L., and DeNardo, S. J. Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: S. W. Burchiel and B. A. Rhodes (eds.), Radioimmunoimaging and Radioimmunotherapy, pp. 41-62. New York: Elsevier Science Publishing Co., 1983.
25. Wessels, B. W., and Rogus, R. D. Radionuclide selection and model absorbed dose calculation for radiolabe led tumor associated antibodies. Med. Phys., 11: 638-645, 1984.
26. 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. Cancer Res., 53: 5727-5733, 1993.
27. 67]Cu-labelled anti-colon carcinoma monoclonal antibody MAB35. Q. J. Nuclear Med., 39: 80, 1995.
28. DeNardo, G. L., DeNardo, S. J., Kukis, D. L., Diril, H., Suey, C., and Meares, C. F. Strategies for enhancement of radioimmunotherapy. Nucl. Med. Biol., 18: 633-640, 1991.
29. DeNardo, G. L., DeNardo, S. J., Meares, C. F., Kukis, D. L., Diril, H., McCall, M. J., Adams, G. P., Mausner, L. F., Moody, D. C., and Deshpande, S. V. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibod. Immunoconjug, Radiopharm., 4: 777-785, 1991.
30. Moi, M. K., Meares, C. F., McCall, M. J., Cole, W. C., and DeNardo, S. J. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem., 148: 249-253, 1985.
31. Epstein, A. L., Zimmer, A. M., and Spies, S. M. Radioimmunodetection of human B-cell lymphomas with a radiolabeled tumor-specific monoclonal antibody (Lym-1). In: F. Cavalli, G. Bonadonna, and M. Rozencweig (eds.), Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, pp. 566-577. Boston: Martinus Nijhoff Publishing Co., 1985.
32. Kukis, D. L., DeNardo, G. L., DeNardo, S. J., Mirick, G. R., Miers, L. A., Greiner, D. P., and Meares, C. F. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT- Lym-1 immunoconjugates. Cancer Res., 55: 878-884, 1995.
33. McCall, M. J., Diril, H., and Meares, C. F. Simplified method for conjugating macrocycle bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconj. Chem., 2: 222-226, 1990.
34. Kukis, D. L., Diril, H., Greiner, D. P., DeNardo, S. J., DeNardo, G. L., Salako, Q. A., and Meares, C. F. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (Phila.), 73 (Suppl.): 779-786, 1994.
35. Kukis, D. L., Li, M., and Meares, C. F. The selectivity of antibodychelate conjugates for binding copper in the presence of competing metals. Inorg. Chem., 32: 3981-3982, 1993.
36. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F-M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
37. Hellström, K. E., Yelton, D. E., Fell, H. P., Beaton, D., Gayle, M., MacLean, M., Kahn, M., and Hellström, I. Epitope mapping and use of anti-idiotopic antibodies to the L6 monoclonal anticarcinoma antibody. Cancer Res., 50: 2449-2454, 1990.
38. Hellström, I., Horn, D., Linsley, P., Brown, J. P., Brankovan, V., and Hellström, K. E. Monoclonal antibodies raised against human lung carcinomas. Cancer Res., 46: 3917-3923, 1986.
39. Penefsky, H. S. A centrifuged-column procedure for the measurement of ligand binding by beef heart F1. Methods Enzymol., 56: 527-530, 1979.
40. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwin, D. A., Diamanti, C. I., and McTigue, M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem., 142: 68-78, 1984.
41. DeNardo, S. J., Peng, J-S. B., DeNardo, G. L., Mills, S. L., and Epstein, A. L. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Nucl. Med. Biol., 13: 303-310, 1986.
42. Beaumier, P. L., Neuzil, D., Yang, H-M., Noll, E. A., Kishore, R., Eary, J. F., Krohn, K. A., Nelp, W. B., Hellström, K. E., and Hellström, I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J. Nucl. Med., 27: 824-828, 1986.
43. DeNardo, S. J., Zhong, G-R., Salako, Q., Li, M., DeNardo, G. L., and Meares, C. F. Pharmacokinetics of chimeric L6 conjugated to indium-Mi- and yttrium-90-DOTA-peptide in tumor-bearing mice. J. Nucl. Med., 36: 829-836, 1995.
44. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res., 52: 6476-6481, 1992.
45. Deshpande, S. V., DeNardo, S. J., Meares, C. F., McCall, M. J., Adams, G. P., Moi, M. K., and DeNardo, G. L. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J. Nucl. Med., 29: 217-225, 1988.
46. 111In-benzyl-EDTA-monoclonal antibody on hepatic uptake and processing in mice. Cancer Res., 49: 1707-1711, 1989.
47. Buchegger, F., Rojas, A., Delaloye, A. B., Vogel, C-A., Mirimanoff, R-O., Coucke, P., Sun, L-Q., Raimondi, S., Denekamp, J., Pélegrin, A., Delaloye, B., and Mach, J-P. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res., 55: 83-89, 1995.
48. Hosono, M., Endo, K., Hosono, M. N., Kobayashi, H., Shirato, M., Sakahara, H., Ueda, R., and Konishi, J. Treatment of small-cell lung cancer xenografts with iodine-131-anti-neural cell adhesion molecule monoclonal antibody and evaluation of absorbed dose in tissue. J. Nucl. Med., 35: 296-300, 1994.
49. Wilder, R. B., McGann, J. K., Sutherland, W. R., Waller, E. K., Minchenton, A. I., Goris, M. L., and Knox, S. J. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int. J. Radiat. Oncol. Biol. Phys., 28: 119-126, 1993.
50. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods, p. 120. New York: Wiley, 1973.
51. Govindarajulu, Z. Statistical Techniques in Bioassay, pp. 5-6. New York: Karger, 1988.
52. Dulbecco, R., and Ginsberg, H. S. The nature of viruses. In: B. D. Davis, R. Dulbecco. H. N. Eisen, and H. S. Ginsberg (eds.), Microbiology, Ed. 3, p. 883. Philadelphia: Harper and Row, 1980.
53. DeNardo, G. L., Kroger, L. A., DeNardo, S. J., Miers, L. A., Salako, Q., Kukis, D. L., Fand, I., Shen, S., Renn, O., and Meares, C. F. Comparative toxicity studies of yttrium-90-MX-DTPA and 2-IT-BAT conjugated monoclonal antibody (BrE-3). Cancer (Phila.), 73 (Suppl.): 1012-1022, 1994.
54. Loevinger, R., and Berman, M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. In: MIRD Pamphlet 1, revised. New York: Society of Nuclear Medicine, 1976.
55. Snyder, W. S., Ford, M. R., and Warner, G. C. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. In: MIRD Pamphlet 5. New York: Society of Nuclear Medicine, 1978.
56. Dillman, L. T., and Von der Lage, F. C. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. In: MIRD Pamphlet 10. New York: Society of Nuclear Medicine, 1975.
57. Siegel, J. A., Wessels, B. W., Watson, E. E., Stabin, M. G., Vriesendorp H. M., Bradley, E. W., Badger, C. C., Brill, A. B., Kwok, C. S., Stickney, D. R., Eckerman, K. F., Fisher, D. R., Buchsbaum, D. J., and Order, S. E. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibod. Immunoconjug. Radiopharm., 3: 213-233, 1990.
58. Casarett, A. P. Acute radiation effects in whole animals. In: A. P. Casarett (ed.), Radiation Biology, pp. 217-235. Edgewood Cliffs, NJ: Prentice-Hall, 1968.
59. Lewis, J. P., O'Grady, L. F., and Green, R. A. Clinical and experimental: patterns of exogenous and endogenous hematopoietic repopulation following radiation injury. J. Lab. Clin. Med., 89: 229-239, 1977.
60. Macklis, R. M., Beresford, B. A., Palayoor, S., Sweeney, S., and Humm, J. L. Cell cycle alterations, apoptosis, and response to low-dose- rate radioimmunotherapy in lymphoma cells. Int. J. Radiat. Oncol. Biol. Phys., 27: 643-650, 1993.
61. Reed, J. C. Mini-review: cellular mechanisms of disease series. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
62. Hu, E., Epstein, A. L., Naeve, G. S., Gill, I., Martin, S., Sherrod, A., Nichols, P., Chen, D., Mazumder, A., and Levine, A. M. A phase la clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol. Oncol., 7: 155-166, 1989.
63. 131I Lym-1 monoclonal antibodies. Int. J. Cancer, 42 (Suppl. 3): 96-101, 1988.
64. 177lutetium-labeled immunoconjugate. Cancer Res., 51: 2889-2896, 1991.
65. Connett, J. M., Guo, L. W., Anderson, C. J., Schwartz, S. W., Zinn, K. R., Philpott, G. W., and Welch, M. J. In vivo toxicity and long-term radioimmunotherapy studies of Cu-64 and Cu-67 anti-colon carcinoma monoclonal antibody (MAb)-1A3 in the GW39-hamster model. J. Nucl. Med., 36 (Suppl.): 92P, 1995.
66. 67Cu from proton irradiated Zn. Appl. Radiat. Isot., 42: 371-376, 1991.
67. Kolsky, K. L., Joshi, V., Meinken, G. E., Sweet, M., Mausner, L. F., and Srivastava, S. C. Improved production and evaluation of Cu-67 for tumor radioimmunotherapy. J. Nucl., Med., 35 (Suppl.): 259P, 1994.
68. Cole, W. C., DeNardo, S. J., Meares, C. F., McCall, M. J., DeNardo, G. L., Epstein, A. L., O'Brien, H. A., and Moi, M. K. Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J. Nucl. Med., 28: 83-90, 1987.
69. 70Zn targets. J. Radioanal. Nucl. Cnem., 195: 263-270, 1995.